Anti-CD19 chimeric antigen receptor (CAR) T cells have emerged as a promising approach to treat B cell malignancies and showed an objective response rate of 52~83% in the pivotal trials JULIET and ZUMA-1 (6–8), resulting in their approval by the Food and Drug Administration (FDA) for patients with NHL. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.